Journal: OncoTargets and therapy
Article Title: The clinicopathological significance of HES1 promoter hypomethylation in patients with colorectal cancer
doi: 10.2147/OTT.S151857
Figure Lengend Snippet: Promoter methylation status of HES1 in CRC tissues and paired normal samples. Notes: ( A ) A schematic illustration of the CpG islands in the HES1 promoter region. ( B ) Representative data of MSP analysis in CRC patients. Experiments were performed in triplicate. T, tumor tissue; N, normal tissue; H 2 O, water control; M, methylated HES1 ; U, unmethylated HES1 ; the numbers at the very top of part B represent the case numbers. Abbreviations: BSP, bisulfite-sequencing PCR; CpG, cytosine-phosphate-guanine; CRC, colorectal cancer; DM, DNA marker; GC, guanine and cytosine; HES1 , hairy/enhancer of split 1; MF1, methylated forward primer 1; MR1, methylated reverse primer 1; MSP, methylation-specific PCR; O/E, observed/expected CpG ratio; PCR, polymerase chain reaction; UF1, unmethylated forward primer 1; UR1, unmethylated reverse primer 1.
Article Snippet: The sequences of bisulfite-sequencing PCR (BSP) primers (GeneCopoeia) were as follows: (forward) 5′-GGAATATTGTATTAAAGGGTAGGTAGG-3′ and (reverse) 5′-TCAATAATTCCTAACTCTAAATA ACC-3′.
Techniques: Methylation, Methylation Sequencing, Marker, Polymerase Chain Reaction

Figure S1 C). (F) Global target DNAme specificity among all probes analyzed. Scatterplots display Infinium probe values for each pairwise comparison (Pearson correlation displayed). Red dots highlight CGs falling within the CIMR DMR (N = 38). (G) The most significant DMR, target MLH1, was specifically and consistently induced across all insert-containing clones (
Table S2 B). DMRs (N = 28) observed between H1 controls and ssI-C1 are displayed by heatmap of mean individual DMR DNAme levels. (H) qRT-PCR analysis of MLH1 expression post CpG-free PI or ssI by the standard curve method. Mean normalized expression ± SE (error bars) to internal control gene TPT1 is displayed (∗p < 0.05, t test). " width="100%" height="100%">
Journal: Cell Reports Methods
Article Title: Engineering CpG island DNA methylation in pluripotent cells through synthetic CpG-free ssDNA insertion
doi: 10.1016/j.crmeth.2023.100465
Figure Lengend Snippet: CIMR overview (A) Briefly, CG-free DNA is integrated in a target CGI by ssDNA/Cas RNP reaction, cells are clonally isolated after CG-free antibiotic selection, and de novo DNAMe assessed. (B) Schematic of CpG-free plasmid-integrated DNA (PI) and shorter CpG-free ssDNA (ssI), with insert-testing primer sites and expected PCR products displayed. (C) Both NeoR gels indicate successful integration of PI and ssI DNA by PCR, as well pilot Cre mRNA mediated removal 48 h post-transfection (right). (D) The first 6 candidate PI and ssI clones are shown. (E) Visualization of EPIC Illumina Infinium array data and target-region-induced DNAme using IgV Viewer (v.2.3). Individual CpG probes with peak intensity corresponding to DNAme level are displayed at the target CGI (DMR in black box). Blue arrows mark bisulfite (BSF)-PCR primers ( Figure S1 C). (F) Global target DNAme specificity among all probes analyzed. Scatterplots display Infinium probe values for each pairwise comparison (Pearson correlation displayed). Red dots highlight CGs falling within the CIMR DMR (N = 38). (G) The most significant DMR, target MLH1, was specifically and consistently induced across all insert-containing clones ( Table S2 B). DMRs (N = 28) observed between H1 controls and ssI-C1 are displayed by heatmap of mean individual DMR DNAme levels. (H) qRT-PCR analysis of MLH1 expression post CpG-free PI or ssI by the standard curve method. Mean normalized expression ± SE (error bars) to internal control gene TPT1 is displayed (∗p < 0.05, t test).
Article Snippet: To easily visualize strong candidate regions, already available bisulfite PCR primer design software is helpful (e.g., methprimer ), as candidate primers are designed specifically to bind more complex sequences of lower GC content and minimal CpGs.
Techniques: Isolation, Selection, Plasmid Preparation, Transfection, Clone Assay, Comparison, Quantitative RT-PCR, Expressing, Control

Figure 1 E for IgV. (C) CIMR DNAme testing guidelines. Briefly, after CGI selection, gRNAs can be ranked for cutting specificity, prevalidated by Surveyor or T7E1 assays, and then paired with a candidate ssDNA repair template. CIMR RNP/ssDNA reactions are followed by antibiotic selection, FACS isolation of single-cell clones as desired, inserts validated by PCR, and DNAme assessed by Infinium analysis or another suitable technique. (D) ONECUT1 CIMRs were tested at 2 different CGIs (
Figure S4 G). (E) Specificity of the edited ONECUT1 CGI is shown by x/y scatterplot of all tested CGs, with 8 altered CGs highlighted in red. (F) TP53 CGI CIMR testing. 4/12 TP53 clones harbored full-length CG-free inserts. (G) Global specificity is shown as in (E), with the 4 CGI spanning probes marked in red. (H and I) TP53 CGI DNAme clones have repressed TP53 (H) and antisense WRAP53 (I) expression (mean normalized expression ± SE (error bars) to internal control TPT1 , ∗p < 0.05, t test). " width="100%" height="100%">
Journal: Cell Reports Methods
Article Title: Engineering CpG island DNA methylation in pluripotent cells through synthetic CpG-free ssDNA insertion
doi: 10.1016/j.crmeth.2023.100465
Figure Lengend Snippet: CIMR testing in other PSCs and CIMP cancer lines, and CIMR testing guidelines (A) Visualization of DMRs by heatmap of DNAme levels across samples. Known CIMP lines have higher CGI DNAme and cluster separately from hypomethylated PSCs. For inclusion, a CGI required a DNAme level of >0.5 in ≥2 samples and an SD of >0.25 (N = 6,062 CGIs). (B) CIMR DNAme occurs in multiple PSCs and embryonal carcinoma Nt2d1 cells but not CIMP cancer lines. See Figure 1 E for IgV. (C) CIMR DNAme testing guidelines. Briefly, after CGI selection, gRNAs can be ranked for cutting specificity, prevalidated by Surveyor or T7E1 assays, and then paired with a candidate ssDNA repair template. CIMR RNP/ssDNA reactions are followed by antibiotic selection, FACS isolation of single-cell clones as desired, inserts validated by PCR, and DNAme assessed by Infinium analysis or another suitable technique. (D) ONECUT1 CIMRs were tested at 2 different CGIs ( Figure S4 G). (E) Specificity of the edited ONECUT1 CGI is shown by x/y scatterplot of all tested CGs, with 8 altered CGs highlighted in red. (F) TP53 CGI CIMR testing. 4/12 TP53 clones harbored full-length CG-free inserts. (G) Global specificity is shown as in (E), with the 4 CGI spanning probes marked in red. (H and I) TP53 CGI DNAme clones have repressed TP53 (H) and antisense WRAP53 (I) expression (mean normalized expression ± SE (error bars) to internal control TPT1 , ∗p < 0.05, t test).
Article Snippet: To easily visualize strong candidate regions, already available bisulfite PCR primer design software is helpful (e.g., methprimer ), as candidate primers are designed specifically to bind more complex sequences of lower GC content and minimal CpGs.
Techniques: Selection, Isolation, Clone Assay, Expressing, Control
Journal: Frontiers in Oncology
Article Title: DNA Demethylation Switches Oncogenic ΔNp63 to Tumor Suppressive TAp63 in Squamous Cell Carcinoma
doi: 10.3389/fonc.2022.924354
Figure Lengend Snippet: Decitabine reduces DNA methylation at the TAp63 promoter. The indicated cell lines were untreated (CTR, DMSO only) or treated with 0.01 µM or 10 µM decitabine for four days. DNA was extracted and bisulfite converted, and PCR products were sequenced to analyze CpG methylation at each of the three individual CpG sites (A–C) . Plots show percentage methylation (n = 2 to 3 biological replicates). Statistical comparisons compare each CpG site in control cells with the same site in decitabine treated cells. **p < 0.01; ***p < 0.001.
Article Snippet: Bisulfite converted PCR primers (Generi Biotech, Hradec Kralove, Czech Republic) were designed according to MethPrimer 2.0 (urogene.org/cgi-bin/methprimer2/MethPrimer.cgi) ( ) ( ) to amplify a 134 bp region beginning 111 bp upstream of the TAP63 transcription start site and containing three CpG sites.
Techniques: DNA Methylation Assay, CpG Methylation Assay, Methylation, Control